Related Experiment Videos
Thrombocytopenia in the newborn.
Irene A G Roberts1, Neil A Murray
1Pediatric Hematology, Imperial College, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom. irene.roberts@ic.ac.uk
Current Opinion in Pediatrics
|January 25, 2003
Summary
Neonatal thrombocytopenia affects many newborns in intensive care. Current platelet transfusion practices lack evidence, highlighting the need for new guidelines and potential growth factor therapies.
Area of Science:
- Neonatal Medicine
- Hematology
Background:
- Thrombocytopenia is a frequent complication in sick newborns, affecting 25% of neonates in intensive care units.
- Severe thrombocytopenia (platelets <50 x 10(9)/L) occurs in 20% of these cases, often linked to conditions like sepsis and necrotizing enterocolitis.
Purpose of the Study:
- To review current understanding and clinical practices surrounding neonatal thrombocytopenia.
- To identify the need for evidence-based transfusion protocols and explore novel therapeutic agents.
Main Methods:
- Literature review of recent studies and clinical reviews on neonatal thrombocytopenia.
- Analysis of current platelet transfusion practices and their efficacy.
Main Results:
- Classifications for neonatal thrombocytopenia have improved clinical management.
- Many neonates receive repeated platelet transfusions with limited evidence of benefit, showing significant practice variation.
Conclusions:
- There is a critical need for evidence-based protocols for platelet transfusion in newborns.
- Hemopoietic growth factors, such as thrombopoietin and interleukin-11, show potential for preventing or treating neonatal thrombocytopenia.